VVY Vivoryon Therapeutics N.V.
Price Chart
Executive Summary
Vivoryon Therapeutics announced it will report Q1 2026 financial results on June 11, 2026, but this is an announcement of the reporting date, not the results themselves. No financial data, guidance, or clinical updates were provided in the press release.
Actionable Insight
The press release is a routine scheduling notice with no material financial or operational information. Monitor the actual Q1 2026 earnings release on June 11, 2026, for cash runway, R&D spend, and any pipeline updates.
Key Facts
- Q1 2026 results to be published on June 11, 2026
- No financial figures, guidance, or clinical updates disclosed in this release
- Company is clinical-stage with focus on kidney disease therapies
- H1 2026 financial and business update conference call expected in August
Financial Impact
No financial data disclosed; announcement of reporting date only
Risk Factors
- No financial data available until June 11, 2026
- Clinical-stage biotech with no approved products; high cash burn risk
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 23, 2026
6w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 15, 2026
8w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 9, 2026
8w ago
|
Press Release
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access